@naggdce@FlyANA_official@MoCA_GoI@jagograhakjago@airsewa_MoCA We travel on ANA multiple times a year and have forgotten ipads, luggage taken by mistake by other customers and it was resolved within a reasonable timeframe. Have faith. ANA will take care of it
💬 Perspective: The dominance of EHR vendor #AI models may reduce incentives for innovation and diversity among third-party health AI tools, raising questions for policymakers.
https://t.co/7VICqVtF5a
@akshaywcam1 so what you’re saying is that there is only one train that goes from the Cuff parade to airport? Mumbai airport is a 24x7 operation. Shouldn’t metro work around the clock with more frequencies? Flights takeoff and land all throughout the day and night, people work there as well
Long term outcomes from POSITIVE (71 mo follow up)
“We could demonstrate that, with long follow up, interrupting ET to achieve pregnancy and resuming ET, does not lead to increased risk of recurrence from breast cancer” @fedrophd
Total of 442 births
👏 #ESMO25#ESMOAmbassadors
Updated safety and the first efficacy data from the PETRANHA trial (Saruparib (AZD5305), a PARP1-selective inhibitor, plus ARPI) in pts with castration-sensitive mPC (mCSPC) and mCRPC 👉excellent talk by @AzadOncology at #ESMO25@OncoAlert@urotoday@PCF_Science
MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma
#ESMO25#ESMOAmbassadors
👉 pCR: 16%, MPR: 26%, any: 87%
👉 OS: HR: 0.78; 36-mo OS: 68 vs 61%
🧐OS improved independent of TAP, better in responders > new SOC
@myesmo
MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma
#ESMO25#ESMOAmbassadors
👉 pCR: 16%, MPR: 26%, any: 87%
👉 OS: HR: 0.78; 36-mo OS: 68 vs 61%
🧐OS improved independent of TAP, better in responders > new SOC
@myesmo